NZ529854A - Group B streptococcus antigens - Google Patents

Group B streptococcus antigens

Info

Publication number: NZ529854A
Authority: NZ; New Zealand
Prior art keywords: polypeptide; seq; polynucleotide; group; exemplified
Prior art date: 1998-02-20

Application number

NZ529854A

Other languages

English (en)

Inventor

Bernard R Brodeur

Clement Rioux

Martine Boyer

Isabelle Charlebois

Josee Hamel

Denis Martin

Original Assignee

Iaf Biochem Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-20

Filing date

2003-11-28

Publication date

2005-08-26

2003-11-28 Application filed by Iaf Biochem Int filed Critical Iaf Biochem Int

2005-08-26 Publication of NZ529854A publication Critical patent/NZ529854A/en

Links

241000193990 Streptococcus sp. 'group B' Species 0.000 title claims description 164
108091007433 antigens Proteins 0.000 title description 18
102000036639 antigens Human genes 0.000 title description 18
239000000427 antigen Substances 0.000 title description 17
108090000765 processed proteins & peptides Proteins 0.000 claims description 128
102000004196 processed proteins & peptides Human genes 0.000 claims description 128
229920001184 polypeptide Polymers 0.000 claims description 127
108091033319 polynucleotide Proteins 0.000 claims description 74
102000040430 polynucleotide Human genes 0.000 claims description 74
239000002157 polynucleotide Substances 0.000 claims description 74
125000003275 alpha amino acid group Chemical group 0.000 claims description 48
210000004027 cell Anatomy 0.000 claims description 46
239000012634 fragment Substances 0.000 claims description 34
239000013598 vector Substances 0.000 claims description 27
238000000034 method Methods 0.000 claims description 21
229960005486 vaccine Drugs 0.000 claims description 20
239000002671 adjuvant Substances 0.000 claims description 17
230000028993 immune response Effects 0.000 claims description 17
239000000203 mixture Substances 0.000 claims description 15
241001465754 Metazoa Species 0.000 claims description 14
238000004519 manufacturing process Methods 0.000 claims description 13
238000011321 prophylaxis Methods 0.000 claims description 7
241000283690 Bos taurus Species 0.000 claims description 6
241000282414 Homo sapiens Species 0.000 claims description 6
230000000295 complement effect Effects 0.000 claims description 5
230000008569 process Effects 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
238000012258 culturing Methods 0.000 claims description 3
230000001939 inductive effect Effects 0.000 claims description 3
230000003248 secreting effect Effects 0.000 claims description 3
208000035143 Bacterial infection Diseases 0.000 claims 3
206010061372 Streptococcal infection Diseases 0.000 claims 3
208000022362 bacterial infectious disease Diseases 0.000 claims 3
230000001225 therapeutic effect Effects 0.000 claims 3
210000005260 human cell Anatomy 0.000 claims 2
238000011065 in-situ storage Methods 0.000 claims 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 69
108090000623 proteins and genes Proteins 0.000 description 66
241000699670 Mus sp. Species 0.000 description 53
102000004169 proteins and genes Human genes 0.000 description 49
235000018102 proteins Nutrition 0.000 description 47
208000015181 infectious disease Diseases 0.000 description 31
230000003053 immunization Effects 0.000 description 25
238000002649 immunization Methods 0.000 description 25
241000194017 Streptococcus Species 0.000 description 23
108020004414 DNA Proteins 0.000 description 22
108091028043 Nucleic acid sequence Proteins 0.000 description 17
108020001507 fusion proteins Proteins 0.000 description 16
102000037865 fusion proteins Human genes 0.000 description 16
239000013612 plasmid Substances 0.000 description 16
241000588724 Escherichia coli Species 0.000 description 15
230000001580 bacterial effect Effects 0.000 description 14
239000002953 phosphate buffered saline Substances 0.000 description 14
230000000890 antigenic effect Effects 0.000 description 12
238000003752 polymerase chain reaction Methods 0.000 description 12
235000001014 amino acid Nutrition 0.000 description 11
229940024606 amino acid Drugs 0.000 description 11
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 10
150000001413 amino acids Chemical class 0.000 description 10
239000007924 injection Substances 0.000 description 10
238000002347 injection Methods 0.000 description 10
210000002966 serum Anatomy 0.000 description 10
230000004083 survival effect Effects 0.000 description 10
238000002965 ELISA Methods 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
241000283973 Oryctolagus cuniculus Species 0.000 description 9
239000012472 biological sample Substances 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
108091008146 restriction endonucleases Proteins 0.000 description 8
239000000725 suspension Substances 0.000 description 8
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
108091026890 Coding region Proteins 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
239000001963 growth medium Substances 0.000 description 7
238000007912 intraperitoneal administration Methods 0.000 description 7
239000000047 product Substances 0.000 description 7
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
241000701022 Cytomegalovirus Species 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
239000011543 agarose gel Substances 0.000 description 6
239000000872 buffer Substances 0.000 description 6
230000004927 fusion Effects 0.000 description 6
150000004676 glycans Chemical class 0.000 description 6
210000003000 inclusion body Anatomy 0.000 description 6
229920001282 polysaccharide Polymers 0.000 description 6
239000005017 polysaccharide Substances 0.000 description 6
210000000952 spleen Anatomy 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
108091034117 Oligonucleotide Proteins 0.000 description 5
108700026244 Open Reading Frames Proteins 0.000 description 5
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
241000193985 Streptococcus agalactiae Species 0.000 description 5
125000000539 amino acid group Chemical group 0.000 description 5
238000000605 extraction Methods 0.000 description 5
239000000499 gel Substances 0.000 description 5
230000000521 hyperimmunizing effect Effects 0.000 description 5
239000002773 nucleotide Substances 0.000 description 5
125000003729 nucleotide group Chemical group 0.000 description 5
238000000746 purification Methods 0.000 description 5
239000003298 DNA probe Substances 0.000 description 4
238000001712 DNA sequencing Methods 0.000 description 4
102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
201000009906 Meningitis Diseases 0.000 description 4
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
229960000723 ampicillin Drugs 0.000 description 4
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
238000002405 diagnostic procedure Methods 0.000 description 4
238000001962 electrophoresis Methods 0.000 description 4
238000012869 ethanol precipitation Methods 0.000 description 4
230000002163 immunogen Effects 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
238000010172 mouse model Methods 0.000 description 4
239000013600 plasmid vector Substances 0.000 description 4
230000009257 reactivity Effects 0.000 description 4
239000000523 sample Substances 0.000 description 4
238000012163 sequencing technique Methods 0.000 description 4
238000011282 treatment Methods 0.000 description 4
238000001262 western blot Methods 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
108010076504 Protein Sorting Signals Proteins 0.000 description 3
238000013019 agitation Methods 0.000 description 3
239000012148 binding buffer Substances 0.000 description 3
239000006161 blood agar Substances 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000001514 detection method Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000006698 induction Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
238000010369 molecular cloning Methods 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
230000001018 virulence Effects 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
101710117545 C protein Proteins 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
108020003215 DNA Probes Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
239000006137 Luria-Bertani broth Substances 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
241000187654 Nocardia Species 0.000 description 2
241001494479 Pecora Species 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
241000191967 Staphylococcus aureus Species 0.000 description 2
241001505901 Streptococcus sp. 'group A' Species 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000009435 amidation Effects 0.000 description 2
238000007112 amidation reaction Methods 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
229940124452 immunizing agent Drugs 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000002054 inoculum Substances 0.000 description 2
229930027917 kanamycin Natural products 0.000 description 2
229960000318 kanamycin Drugs 0.000 description 2
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
229930182823 kanamycin A Natural products 0.000 description 2
231100000518 lethal Toxicity 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
208000004396 mastitis Diseases 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
229910052759 nickel Inorganic materials 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
239000012071 phase Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
230000005180 public health Effects 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
230000004044 response Effects 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
238000012546 transfer Methods 0.000 description 2
238000013519 translation Methods 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
229940124856 vaccine component Drugs 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
DLZKEQQWXODGGZ-KCJUWKMLSA-N 2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DLZKEQQWXODGGZ-KCJUWKMLSA-N 0.000 description 1
101150110188 30 gene Proteins 0.000 description 1
-1 AlK(SOJj Chemical class 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000228212 Aspergillus Species 0.000 description 1
241000228245 Aspergillus niger Species 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101710150468 C protein alpha-antigen Proteins 0.000 description 1
101100191768 Caenorhabditis elegans pbs-4 gene Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
208000004145 Endometritis Diseases 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
206010058780 Meningitis neonatal Diseases 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
208000006816 Neonatal Sepsis Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
239000001888 Peptone Substances 0.000 description 1
108010080698 Peptones Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
101150016011 RR11 gene Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
241000702208 Shigella phage SfX Species 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
241000187747 Streptomyces Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
101710137500 T7 RNA polymerase Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
238000007818 agglutination assay Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
238000000137 annealing Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
230000009920 chelation Effects 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 1
239000013611 chromosomal DNA Substances 0.000 description 1
230000000112 colonic effect Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
238000013461 design Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000012520 frozen sample Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
244000144980 herd Species 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000002955 isolation Methods 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
238000002372 labelling Methods 0.000 description 1
101150109249 lacI gene Proteins 0.000 description 1
101150066555 lacZ gene Proteins 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
239000002523 lectin Substances 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
239000007788 liquid Substances 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
238000001325 log-rank test Methods 0.000 description 1
239000006166 lysate Substances 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
101150023497 mcrA gene Proteins 0.000 description 1
239000002184 metal Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000001823 molecular biology technique Methods 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
239000003921 oil Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
235000019319 peptone Nutrition 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
101150022503 phoR gene Proteins 0.000 description 1
229940080469 phosphocellulose Drugs 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000011555 rabbit model Methods 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
238000000527 sonication Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
238000010186 staining Methods 0.000 description 1
ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 1
125000004149 thio group Chemical group *S* 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
101150057627 trxB gene Proteins 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
239000004474 valine Substances 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

NZ529854A 1998-02-20 2003-11-28 Group B streptococcus antigens NZ529854A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US7542598P	1998-02-20	1998-02-20

Publications (1)

Publication Number	Publication Date
NZ529854A true NZ529854A (en)	2005-08-26

Family

ID=22125658

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NZ529854A NZ529854A (en)	1998-02-20	2003-11-28	Group B streptococcus antigens

Country Status (22)

Country	Link
US (4)	US20030031682A1 (zh)
EP (3)	EP2280072B1 (zh)
JP (2)	JP4637350B2 (zh)
KR (1)	KR100771148B1 (zh)
CN (2)	CN1944652A (zh)
AP (1)	AP2000001886A0 (zh)
AT (1)	ATE347600T1 (zh)
AU (1)	AU2505999A (zh)
CA (1)	CA2321106C (zh)
CZ (1)	CZ301056B6 (zh)
DE (1)	DE69934299T2 (zh)
EA (1)	EA200000860A1 (zh)
ES (2)	ES2278436T3 (zh)
HU (1)	HU228497B1 (zh)
ID (1)	ID27482A (zh)
IL (3)	IL137921A0 (zh)
NO (2)	NO330491B1 (zh)
NZ (1)	NZ529854A (zh)
OA (1)	OA11686A (zh)
TR (1)	TR200002437T2 (zh)
WO (1)	WO1999042588A2 (zh)
ZA (1)	ZA991325B (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4637350B2 (ja)	1998-02-20	2011-02-23	アイディ・バイオメディカル・コーポレイション	グループｂ連鎖球菌抗原
US7098182B2 (en)	1998-07-27	2006-08-29	Microbial Technics Limited	Nucleic acids and proteins from group B streptococcus
JP2002531054A (ja) *	1998-07-27	2002-09-24	マイクロビアルテクニクスリミティッド	Ｂ群連鎖球菌由来の核酸およびタンパク質
EA004444B1 (ru)	1998-12-22	2004-04-29	Майкросайенс Лимитед	Гены и белки и их применение
US6890539B2 (en)	1998-12-22	2005-05-10	Microscience, Ltd.	Genes and proteins, and their use
GB0105922D0 (en) *	2001-03-09	2001-04-25	Microscience Ltd	Genes and proteins, and their use
US7128918B1 (en)	1998-12-23	2006-10-31	Id Biomedical Corporation	Streptococcus antigens
US6833356B1 (en)	1999-08-25	2004-12-21	Medimmune, Inc.	Pneumococcal protein homologs and fragments for vaccines
CA2382795A1 (en) *	1999-08-25	2001-03-01	Medimmune, Inc.	Homologs of a pneumococcal protein and fragments for vaccines
US6866855B2 (en)	2000-06-12	2005-03-15	University Of Saskatchewan	Immunization of dairy cattle with GapC protein against Streptococcus infection
US6833134B2 (en)	2000-06-12	2004-12-21	University Of Saskacthewan	Immunization of dairy cattle with GapC protein against Streptococcus infection
EP1734050A3 (en) *	2000-06-12	2012-12-05	University Of Saskatchewan	Immunization of dairy cattle with GapC protein against streptococcus infection
WO2001096381A2 (en) *	2000-06-12	2001-12-20	University Of Saskatchewan	IMMUNIZATION OF DAIRY CATTLE WITH GapC PROTEIN AGAINST STREPTOCOCCUS INFECTION
DK1294771T3 (da)	2000-06-12	2008-12-15	Univ Saskatchewan	Kimært GapC-protein fra Streptococcus og anvendelse deraf til vaccinering og diagnosticering
ATE547527T1 (de)	2000-10-13	2012-03-15	Id Biomedical Corp	Gruppe b streptococcus bvh-a2 und bvh-a3 antigene
NZ594877A (en)	2000-10-27	2012-07-27	Novartis Vaccines & Diagnostic	Nucleic acids and proteins from streptococcus groups A & B
JP4080876B2 (ja) *	2000-12-21	2008-04-23	アイディーバイオメディカルコーポレイション	ストレプトコッカス・ピオゲネス抗原及び対応するｄｎａフラグメント
FR2824074A1 (fr) *	2001-04-26	2002-10-31	Pasteur Institut	Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques
ES2381967T3 (es) *	2002-02-11	2012-06-04	Id Biomedical Corporation	Antígeno de streptococcus del grupo B
GB0210128D0 (en) *	2002-05-02	2002-06-12	Chiron Spa	Nucleic acids and proteins from streptococcus groups A & B
PT1648500E (pt)	2003-07-31	2014-10-10	Novartis Vaccines & Diagnostic	Composições imunogénicas para estreptococos piogenes
US8945589B2 (en)	2003-09-15	2015-02-03	Novartis Vaccines And Diagnostics, Srl	Immunogenic compositions for Streptococcus agalactiae
US20090317420A1 (en)	2004-07-29	2009-12-24	Chiron Corporation	Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
WO2006042027A2 (en)	2004-10-08	2006-04-20	Novartis Vaccines And Diagnostics Inc.	Immunogenic and therapeutic compositions for streptococcus pyogenes
WO2006086330A2 (en) *	2005-02-08	2006-08-17	Id Biomedical Corporation Of Quebec C.O.B. As Glaxosmithkline Biologicals North America	Pharmaceutical compositions
GB0605247D0 (en) *	2006-03-15	2006-04-26	Chiron Srl	Compositions and methods for immunisation
EP2197485B1 (en)	2007-09-12	2015-11-11	GlaxoSmithKline Biologicals SA	Gas57 mutant antigens and gas57 antibodies
PL2235046T3 (pl)	2007-12-21	2012-12-31	Novartis Ag	Zmutowane formy streptolizyny O
CN102304185A (zh) *	2011-09-02	2012-01-04	黑龙江八一农垦大学	预防奶牛乳房炎的融合蛋白sip-trap及制备方法和应用
EP2949340A1 (en) *	2014-05-30	2015-12-02	IDT Biologika GmbH	Vaccine composition against Streptococcus suis infection
CN115057944B (zh) *	2022-06-24	2025-06-24	南京农业大学	一种针对所有gbs血清型的多表位亚单位疫苗

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4431739A (en)	1979-11-05	1984-02-14	Genentech, Inc.	Transformant bacterial culture capable of expressing heterologous protein
US4425437A (en)	1979-11-05	1984-01-10	Genentech, Inc.	Microbial polypeptide expression vehicle
US5302386A (en)	1986-04-16	1994-04-12	Brigham And Women's Hospital, Inc.	Bacterial antigens, antibodies, vaccines and methods of manufacture
US5472696A (en)	1988-02-26	1995-12-05	Univ. Of Florida Research Foundation, Inc.	Antigen of group B streptococci
US5648241A (en) *	1989-09-15	1997-07-15	The General Hospital Corporation	Conjugate vaccine against group B streptococcus
US5679768A (en)	1991-02-15	1997-10-21	Uab Research Foundation	Epitopic regions of pneumococcal surface protein A
US5225331A (en)	1991-04-25	1993-07-06	National Research Council Of Canada	Immunoassay for detecting group b streptococcus
SG47049A1 (en)	1993-03-19	1998-03-20	Gunnar Lindahl	Protein rib a cell surface protein that confers immunity to manu strains of the group b strepto-ccus process for purification of the protein reagent kit
US5595740A (en)	1994-05-16	1997-01-21	University Of Florida	Cloning of non-IgA FC binding forms of the group B streptococcal beta antigens
WO1996013516A1 (en) *	1994-11-01	1996-05-09	Kirin Beer Kabushiki Kaisha	Peptide sequence that forms mucin sugar chain and technique for modifying protein to be linked with mucin sugar chain
US6420135B1 (en) *	1996-10-31	2002-07-16	Human Genome Sciences, Inc.	Streptococcus pneumoniae polynucleotides and sequences
JP4637350B2 (ja) *	1998-02-20	2011-02-23	アイディ・バイオメディカル・コーポレイション	グループｂ連鎖球菌抗原
US6248329B1 (en) *	1998-06-01	2001-06-19	Ramaswamy Chandrashekar	Parasitic helminth cuticlin nucleic acid molecules and uses thereof
JP2002531054A (ja)	1998-07-27	2002-09-24	マイクロビアルテクニクスリミティッド	Ｂ群連鎖球菌由来の核酸およびタンパク質
JP4689044B2 (ja)	1998-12-21	2011-05-25	メディミューン，インコーポレーテッド	ワクチン用の肺炎連鎖球菌タンパク質と免疫原断片
CA2356836C (en)	1998-12-23	2011-09-13	Shire Biochem Inc.	Novel streptococcus antigens
US7128918B1 (en) *	1998-12-23	2006-10-31	Id Biomedical Corporation	Streptococcus antigens
GB9921125D0 (en)	1999-09-07	1999-11-10	Microbial Technics Limited	Proteins
ES2381967T3 (es)	2002-02-11	2012-06-04	Id Biomedical Corporation	Antígeno de streptococcus del grupo B

1999
- 1999-02-17 JP JP2000532528A patent/JP4637350B2/ja not_active Expired - Lifetime
- 1999-02-17 CA CA2321106A patent/CA2321106C/en not_active Expired - Lifetime
- 1999-02-17 HU HU0102304A patent/HU228497B1/hu unknown
- 1999-02-17 AP APAP/P/2000/001886A patent/AP2000001886A0/en unknown
- 1999-02-17 WO PCT/CA1999/000114 patent/WO1999042588A2/en not_active Ceased
- 1999-02-17 ES ES99904646T patent/ES2278436T3/es not_active Expired - Lifetime
- 1999-02-17 CN CNA2006100913640A patent/CN1944652A/zh active Pending
- 1999-02-17 OA OA1200000228A patent/OA11686A/en unknown
- 1999-02-17 KR KR1020007009237A patent/KR100771148B1/ko not_active Expired - Lifetime
- 1999-02-17 AT AT99904646T patent/ATE347600T1/de not_active IP Right Cessation
- 1999-02-17 IL IL13792199A patent/IL137921A0/xx active IP Right Grant
- 1999-02-17 ES ES10180962.2T patent/ES2540281T3/es not_active Expired - Lifetime
- 1999-02-17 CZ CZ20003054A patent/CZ301056B6/cs not_active IP Right Cessation
- 1999-02-17 AU AU25059/99A patent/AU2505999A/en not_active Abandoned
- 1999-02-17 ID IDW20001856A patent/ID27482A/id unknown
- 1999-02-17 EP EP10180962.2A patent/EP2280072B1/en not_active Expired - Lifetime
- 1999-02-17 CN CNB998052485A patent/CN1268745C/zh not_active Expired - Lifetime
- 1999-02-17 TR TR2000/02437T patent/TR200002437T2/xx unknown
- 1999-02-17 DE DE69934299T patent/DE69934299T2/de not_active Expired - Lifetime
- 1999-02-17 EP EP20060022306 patent/EP1757697A3/en not_active Withdrawn
- 1999-02-17 EP EP99904646A patent/EP1054971B1/en not_active Expired - Lifetime
- 1999-02-17 EA EA200000860A patent/EA200000860A1/ru unknown
- 1999-02-18 ZA ZA9901325A patent/ZA991325B/xx unknown
- 1999-02-18 US US09/252,088 patent/US20030031682A1/en active Pending
2000
- 2000-08-17 IL IL137921A patent/IL137921A/en not_active IP Right Cessation
- 2000-08-18 NO NO20004161A patent/NO330491B1/no not_active IP Right Cessation
2003
- 2003-01-13 US US10/340,792 patent/US7914794B2/en not_active Expired - Lifetime
- 2003-11-28 NZ NZ529854A patent/NZ529854A/en not_active IP Right Cessation
2008
- 2008-03-09 IL IL190018A patent/IL190018A/en not_active IP Right Cessation
2009
- 2009-06-02 JP JP2009132976A patent/JP2009242403A/ja active Pending
2010
- 2010-11-30 NO NO20101682A patent/NO20101682L/no not_active Application Discontinuation
- 2010-12-28 US US12/980,172 patent/US8226953B2/en not_active Expired - Fee Related
2012
- 2012-07-16 US US13/550,363 patent/US8580262B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1757697A3 (en)	2007-05-30
NO20004161D0 (no)	2000-08-18
OA11686A (en)	2005-01-12
ES2540281T3 (es)	2015-07-09
WO1999042588A3 (en)	2000-03-23
CN1297482A (zh)	2001-05-30
AU2505999A (en)	1999-09-06
DE69934299D1 (de)	2007-01-18
EP2280072A3 (en)	2012-06-06
KR20010034518A (ko)	2001-04-25
HUP0102304A3 (en)	2008-03-28
CA2321106A1 (en)	1999-08-26
ES2278436T3 (es)	2007-08-01
IL190018A (en)	2011-07-31
CZ20003054A3 (cs)	2001-03-14
CA2321106C (en)	2013-07-23
IL190018A0 (en)	2008-08-07
US20130095498A1 (en)	2013-04-18
EA200000860A1 (ru)	2001-10-22
US8226953B2 (en)	2012-07-24
KR100771148B1 (ko)	2007-10-29
WO1999042588A2 (en)	1999-08-26
CN1944652A (zh)	2007-04-11
EP1054971A2 (en)	2000-11-29
IL137921A (en)	2008-06-05
JP2002507396A (ja)	2002-03-12
EP2280072A2 (en)	2011-02-02
EP1054971B1 (en)	2006-12-06
US20030031682A1 (en)	2003-02-13
US20030228323A1 (en)	2003-12-11
DE69934299T2 (de)	2007-07-05
US7914794B2 (en)	2011-03-29
ZA991325B (en)	1999-08-20
ATE347600T1 (de)	2006-12-15
ID27482A (id)	2001-04-12
HU228497B1 (en)	2013-03-28
TR200002437T2 (tr)	2000-11-21
EP1757697A2 (en)	2007-02-28
CN1268745C (zh)	2006-08-09
JP2009242403A (ja)	2009-10-22
US8580262B2 (en)	2013-11-12
CZ301056B6 (cs)	2009-10-29
AP2000001886A0 (en)	2000-09-30
NO330491B1 (no)	2011-05-02
EP2280072B1 (en)	2015-03-25
NO20004161L (no)	2000-10-19
US20110182923A1 (en)	2011-07-28
HUP0102304A1 (hu)	2001-10-28
NO20101682L (no)	2000-10-19
JP4637350B2 (ja)	2011-02-23
IL137921A0 (en)	2001-10-31

Publication	Publication Date	Title
US8580262B2 (en)	2013-11-12	Group B Streptococcus antigens
EP2261358B1 (en)	2014-05-14	Novel streptococcus antigen
US7262024B2 (en)	2007-08-28	Streptococcus antigens
AU2007200130B2 (en)	2007-02-15	Group B Streptococcus Antigens
AU2007202175B2 (en)	2010-07-15	Group B Streptococcus Antigens
EP1325133B1 (en)	2012-02-29	Bvh-a2 and bvh-a3 antigens of group b streptococcus
EP1950302B1 (en)	2012-12-05	Streptococcus antigens
HK1100752A (zh)	2007-09-28	B群链球菌抗原
HK1118575B (zh)	2013-04-26	链球菌抗原
MXPA00008111A (en)	2002-03-05	Group b streptococcus antigens

Legal Events

Date	Code	Title	Description
2005-12-23	PSEA	Patent sealed
2006-02-24	RENW	Renewal (renewal fees accepted)
2006-03-31	RENW	Renewal (renewal fees accepted)
2007-10-26	ASS	Change of ownership	Owner name: ID BIOMEDICAL CORPORATION, CA Free format text: OLD OWNER(S): BIOCHEM PHARMA INC.
2009-02-27	RENW	Renewal (renewal fees accepted)
2012-01-27	RENW	Renewal (renewal fees accepted)
2019-02-22	EXPY	Patent expired